Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Alzamend Neuro, Inc.

35 indications, side-by-side phase, drug & LoA

$1.21

+0.06 (+5.68%)

D 22Pipeline Score Richly Valued Pharma · Clinical
Market Cap
4.34 M
EPS
-4.38
P/E Ratio
-0.26 $
Value Trade
38.93 K
SEC Financials
Q1 2026

  • Dilution Risk

    95%

  • R&D Expenses

    1.28 M

  • Total Assets

    4.04 M

  • Total Liabilities

    1.86 M

  • Equity

    2.18 M

  • D/E Ratio

    12,345

11.88 %
Week
2.73 %
1 Month
-43.5 %
3 Month
-43.5 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Critical

  • Cash Position

    2.71 M

  • Monthly Burn

    733.00 K

  • Runway

    0.7 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    Mar 11, 2026
Overview
Volume
61.21 K
52 Week Range
0.84 - 4.03
% held by Insiders
16.05 %
% held by Institutions
3.04 %
Enterprise Value
1.62 M
Total Shares
3.81 M
Short %
3.97 %
Float Shares
3.75 M
Company Description
HQ: 480 PEACHTREE ROAD NE, SECOND ...
Founded:2016
Employees:7
https://www.alzamend.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 2 data readout example
AL001 Alzheimer's disease (treatment / cognitive endpoints)
Phase 2
—
-
-
AL001 Alzheimer's disease (treatment / cognitive endpoints)
Phase 2
—
-
-
AL001 Alzheimer's disease (treatment / cognitive endpoints)
Phase 2
—
-
-
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D22
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 21%
Micro Cap
(rank 716 of 905)
Percentile Rank
Alzamend Neuro, Inc. faces pipeline headwinds (22/100), with $51M risk-adjusted pipeline value, led by AL001 in Bipolar I Disorder (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
AL001
Small molecule		PharmacokineticsPhase 1NCT069215907% $51M ACTIVE NOT_RECRUITING 6 STALLED D (38) Dec 1, 2025MODERATE_RISKLOW
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
AL001
Alzheimer's,bipolar disorder,major depressive disorder,post-traumatic stress disorder
Phase 2
2025-07-29
AL001
Alzheimer's,bipolar disorder,major depressive disorder,post-traumatic stress disorder
Phase 2
2025-07-29
AL001
Alzheimer's,bipolar disorder,major depressive disorder,post-traumatic stress disorder
Phase 2
2025-07-29
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in ALZN
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ALZN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ALZN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ALZN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
ALZN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
ALZN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Alzamend Neuro, Inc. (ALZN) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How ALZN ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Bipolar Disorder #11 of 12 PHASE 1 AL001 + Lithium carbonate
BMY ABBV ALKS
$10.5B 0 FOLLOWER
Alzheimer's Disease #19 of 24 PHASE 1 ALZN002 .
BMY LLY BIIB
$6.49B 0.9 FOLLOWER